Polymer-drug conjugates: present state of play and future perspectives.

Polymer conjugation is an efficient approach to improve therapeutic properties of drugs and biological agents. Since the first synthetic polymer-drug conjugate entered clinical trials in 1994, this technology has undergone notable development for the introduction and study of novel polymers and for the progress in the biological rationale for designing conjugates. Not surprisingly, new polymers, in addition to the best known polyethylene glycol, poly[N-(2-hydroxypropyl)methacrylamide], are continuously conjugated with drugs to achieve biodegradable, stimuli-sensitive and targeted systems in an attempt to prolong blood circulation times and enhance drug concentrations at the intended site of action.

[Preparation and in vitro characterization of apigemin-loaded nanostructured lipid carriers].

Objective: To prepare Apigemin-loaded nanostructured lipid carriers (Api-NLCs) and evaluate their characteristics.

Methods: Api-NLCs were prepared by the method of emulsion evaporation-solidification at low temperature. The physicochemical properties such as morphology, size distribution, zeta potential, entrapment efficiency, drug loading and drug release in vitro were evaluated.

[Preparation and characterization of curcumin polybutylcyanoacrylate nanoparticles].

Objective: To prepare curcumin polybutylcyanoacrylate nanoparticles (Cur-PBCNs) and evaluate its characteristics.

Methods: Cur-PBCNs were prepared by emulsion polymerization, and the formulation was optimized by L16 (4(3)) orthogonal design test with entrapment efficiency and drug loading as indices. In addition, its characteristics were investigated.